Key result
Switching to a triple fixed-dose combination of perindopril, indapamide, and amlodipine significantly reduced mean office blood pressure by 24.81/11.41 mm Hg (p<0.0001) at 3 months.
Why the study?
Most patients with arterial hypertension require combination therapy for blood pressure control, with about 30% needing three drugs from different classes, prompting evaluation of a once-daily triple fixed combination in real clinical practice.
Does a once-daily triple fixed-dose combination of perindopril, indapamide, and amlodipine reduce blood pressure in ambulatory patients with arterial hypertension?
Observational (n=11,209)
Open-label
Does a once-daily triple fixed-dose combination of perindopril, indapamide, and amlodipine reduce blood pressure in ambulatory patients with arterial hypertension?
A once-daily triple fixed-dose combination of perindopril, indapamide, and amlodipine significantly reduces blood pressure and improves metabolic parameters in ambulatory patients with arterial hypertension.
Answers are grounded in this paper and cite their sources.
Supports real-world BP control with perindopril/indapamide/amlodipine triple combination; leaves open randomized confirmation.
Most patients with arterial hypertension (AH) for successful long-term blood pressure (BP) control require combination of antihypertensive drugs acting on various target organs. Accumulated experience shows that about 30 % of patients require combination therapy with 3 drugs from different pharmacological classes. Efficacy of BP control in real clinical practice with the use of various doses of perindopril, indapamide, and amlodipine as components of taken once-daily triple fixed combination was assessed in the 3-months prospective observational open-label PETRA study. In this study data of office BP measurements and 24-hour ambulatory BP monitoring (ABPM) were obtained from 11209 ambulatory patients (47.6 % women) with AH. Initial mean office BP (BPmoff) was 156.58±16.10 / 91.56±9.33 mm Hg, AH duration - 9.48±7.19 years. After switching to triple fixed dose combination of perindopril, indapamide, and amlodipine BPmoff decreased by 24.81±15.47 / 11.41±9.90 mm Hg (p<0.0001). Doses of perindopril, indapamide, and amlodipine in combination at the final visit were 5 / 1.25 / 5, 10 / 2.5 / 5, and 10 / 2.5 / 10 mg. 24-hour ambulatory BP monitoring (ABPM) was carried out in 76 patients. Mean 24-hour BP lowed from mean 155.51±17.43 / 85.28±11.48 down to 134.63±12.51 / 77.83±8.99 mm Hg (p<0.0001). Clinically relevant improvement of a number of parameters of metabolism occurred after 3 months of the study (in particular, lowering of levels of total and low-density lipoprotein cholesterol [-8.6 and - 11.4 %, respectively], triglycerides [-12,1 %], fasting blood glucose [-6.6 %]). Thus, results of the PETRA study confirmed 24-hour long antihypertensive efficacy of triple fixed dose combination of perindopril, indapamide, and amlodipine. This drug combination can present novel possibility in treatment of patients with AH who have not achieved target BP values on preceding dual combination therapy and fully corresponds with the single pill concept for formation of adherence to therapy.
No takes yet. Share an insight, caveat, or question.
Привалова et al. (2018) conducted an observational in arterial hypertension (n=11,209). Triple fixed-dose combination of perindopril, indapamide, and amlodipine was evaluated on Change in mean office blood pressure (decrease of 24.81 / 11.41 mm Hg, p=<0.0001). Switching to a triple fixed-dose combination of perindopril, indapamide, and amlodipine significantly reduced mean office blood pressure by 24.81/11.41 mm Hg (p<0.0001) at 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: